Gastric cancer and colorectal cancer have something in common

Share This Post

Researchers at the Duke University Cancer Institute have found that H. pylori may lead to an increased risk of colorectal cancer, especially for people with color. People of color are more likely to be diagnosed and die of colorectal cancer.

The researchers further explored the link between H. pylori and colorectal cancerMore than half of the world’s population is infected with Helicobacter pylori, bacteria can cause gastric cancer and gastric ulcers. Researchers at Duke University collected samples from subjects of different races and checked antibody levels before cancer developed. Half of the more than 8,000 study participants continue to develop colorectal cancer. To determine whether the presence of antibodies increased the likelihood of developing colorectal cancer, the researchers compared the frequency of antibodies between cancer and non-cancer subjects. They observed similar rates of past infections in the two groups. As a result, a higher percentage of black and Latino subjects had H. pylori antibodies. This finding is consistent in both cancer and non-cancer tissues. Antibodies specific for Helicobacter pylori proteins are most commonly found in different ethnic groups. Most importantly, a high-level antibody to the H. pylori protein-VacA protein is closely related to the incidence of colorectal cancer in African-American and Asian Americans. 

The association between H. pylori and colorectal cancer plays a role in people of color and can significantly affect treatment options, action plans, and public health differences related to cancer. Medical professionals can identify high-risk people with colorectal cancer based on the status of Helicobacter pylori and reduce the incidence of cancer through treatment.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy